It's a clown show. Reminds me of when Zoom video became a $150B company because "vid chat."
The market loves stories and right now the story is that being overweight is so 2010's.
It's obvious that being overweight impacts just about every health metric. I'm not sure how many more of these studies NVO and LLY can parade around before the market tires of the same story being repackaged over and over.
Don't forget the impact to food stocks like PEP and KO.
Also impacting aesthetics companies like RVNC imo—the narrative being that people would rather use their money for weight loss copays or self-pay than toxins.
Dew. re " Its a clown show " post you have highlighted above . Care to explain why you would high light such a post ? The poster has no idea of the risk reduction seen in NVO's CKD trial that was stopped for efficacy . But IMHO its no small thing to stop a major trial at interim for efficacy so its unlikely to be a clown show for those with CKD heading towards ESRD You probably have some idea of what % of trials are stopped this way . Kiwi
Market Data 
Markets 
AI
